DDInter1824 DDInter1435
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tociliz
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isradipine
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dienogest
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Canakinumab
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Isradipine
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Tocilizumab may lead to a major life threatening interaction when taken with Fingolimod
Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab